Clinical Trials Browser

Recruiting × Thymoma × pembrolizumab × Clear all

NCT03295227 2026-01-30

Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer

Phase 1 Recruiting

Thymoma

NCT03463460 2025-08-24

Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer

Phase 2 Recruiting

Thymoma

NCT05832827 2023-10-23

Artemis

Phase 2 Recruiting

Thymoma